July 1st 2025 – Remedy Biologics is pleased to announce that Ashley Nagle has been appointed to its Board of Directors, effective immediately.
Mr. Nagle will contribute strategic oversight into business development, alliances, and the commercialisation of Remedy Biologics’ therapeutic platforms. Mr. Nagle’s extensive track record, including executive and governance roles at biotechnology companies including Domain Therapeutics, Epsilogen, Seagull Tx, Oncosynergy, and Fulcrum Pharma, positions him well to help deepen our collaborative networks and accelerate the translation of our technology into clinical impact.
Mr. Nagle also previously served the company as Vice President of Business Development, bringing wide experience in structuring transactions, technology partnerships, and early-stage asset development across both large and emerging biopharma organisations.
Dan Crowley, Chief Executive at Remedy Biologics, said:
“Ashley brings decades of experience in building partnerships to leverage advanced new technologies and therapeutics. His insight and leadership will contribute immensely to the company’s journey.”
Ashley Nagle commented:
“RemedyBio’s technology allows us to map immune‑disease interactions at a scale and depth previously unimagined, creating insights which can change how major diseases are treated. I’m excited to contribute to realising the company’s immense potential.”
Mr. Nagle’s appointment to the Board is effective as of July 2025.
